The postoperative care of malignant hyperthermia (MH) patients is subject to international variation, with a paucity of data in the literature to guide management. Over a series of three studies, our aim was to evaluate whether MH-susceptible patients (and relatives who had not yet been investigated), who had received a non-triggering anaesthetic, could be managed in the same way as the standard surgical population. Following a retrospective study, 206 anaesthetics were administered in a prospective second study to MH-susceptible/related individuals who were monitored for a minimum of one hour in the post anaesthesia care unit and a further 90 minutes in a step-down facility. No problems relating to MH were encountered. The postoperative monitoring time was subsequently changed and, in a third study, patients were managed no differently from standard surgical patients. One hundred and twenty-five anaesthetics were administered with no evidence of problems. This data shows that standard postoperative monitoring times are safe and appropriate in MH-susceptible patients.
The European Malignant Hyperpyrexia Group.A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility.Br J Anaesth1984; 56: 1267–1269.
9.
European Malignant Hyperthermia Group 32nd Annual Meeting, Basel, Switzerland, May 2013.
YentisS.M., LevineM.F., HartleyE.J.Should all children with suspected or confirmed malignant hyperthermia susceptibility be admitted after surgery? A 10-year review.Anesth Analg1992; 75: 345–350.
12.
BrandomB.W.Ambulatory surgery and malignant hyperthermia.Current Opinion in Anesthesiology2009; 22: 744–747.
13.
PollockN., LangtonE., McDonnellN., TiemessenJ., StowellK.Malignant hyperthermia and day stay surgery.Anaesth Intensive Care2006; 34: 40–45.
14.
RawalN.Analgesia for day-case surgery.Br J Anaesth2001; 87: 73–87.
KolbM.E.M., HorneM.L.M., MartzR.R.Dantrolene in human malignant hyperthermia.Anesthesiology1982; 56: 254–262.
18.
LitmanR.S., FloodC.D., KaplanR.F., KimY.L., TobinJ.R.Postoperative malignant hyperthermia: an analysis of cases from the North American Malignant Hyperthermia Registry.Anesthesiology2008; 109: 825–829.
YamashitaM., HondaK., IhaH., KondoS., MatsukiA., OyamaT.A case of acute hyperpyrexia with violent shivering immediately after operation under epidural anaesthesia supplemented by nitrous oxide.Can Anesth Soc J1982; 29: 632–635.
28.
HunterS.L., RosenbergH., TuttleG.H., DeWaltJ.L., SmodicR., MartinJ.Malignant Hyperthermia in a college football player.Phys Sportsmed1987; 15: 77–85.
29.
CarrA.S., LermanJ., CunliffeM., McLeodM.E., BrittB.A.Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy.Can J Anesth1995; 42: 281–286.
30.
FletcherR., RanklevE., OlssonA., LeanderS.Malignant hyper-thermia syndrome in an anxious patient.Br J Anaesth1981; 53: 993.
31.
KempD.R., ChoongL.S.Malignant hyperthermia and the conscious patient.Aust N Z J Surg1988; 58: 423–437.
32.
FeuermanT., GadeG.F., ReynoldsR.Stress induced malignant hyperthermia in a head injured patient.J Neurosurg1988; 68: 297–299.
ShukryM., GuruliZ.V., RamadhyaniU.Suspected malignant hyper-thermia in a child with laminin alpha2 (merosin) deficiency in the absence of a triggering agent.Paediatr Anaesth2006; 16: 462–465.
35.
LarachM.G., GronertG.A., AllenG.C., BrandomB.W., LehmanE.B.Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006.Anesth Analg2010; 110: 498–507.
DurhamW.J., Aracena-ParksP., LongC., RossiA.E., GoonasekeraS.A., BoncompagniS.RyR1 S-Nitrosylation Underlies Environmental Heat Stroke and Sudden Death in Y522S RyR1 Knockin Mice.Cell2008; 133: 53–65.
40.
GronertG.A., ThompsonR.L., OnofrioB.M.Human malignant hyperthermia: awake episodes and correction by dantrolene.Anesth Analg1980; 59: 377–378.
41.
PoelsP.J.E., JoostenE.M.G., SengersR.C.A., StadhoudersA.M., VeerkampJ.H., BendersAAGM. In vitro contraction test for malignant hyper-thermia in patients with unexplained recurrent rhabdomyolysis.J Neuro Sci1991; 105: 67–72.
ThomasJ., CrowhurstT.Exertional heat stroke, rhabdomyolysis and susceptibility to malignant hyperthermia.Intern Med J2013; 43: 1035–1038.
50.
DavisM., BrownR., DicksonA., HortonH., JamesD., LaingN.Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees.Br J Anaesth2002; 88: 508–515.
51.
DlaminiN., VoermansN.C., LillisS., StewartK., KamsteegE.J., DrostG.Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis.Neuromuscul Disord2013; 23: 540–548.
52.
WapplerF., FiegeM., SteinfathM., AgarwalK., ScholzJ., SunghS.Evidence of susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis.Anesthesiology2001; 94: 95–100.
53.
CarsanaA.Exercise-induced rhabdomyolysis and stress-induced malignant hyperthermia events, association with malignant hyperthermia susceptibility, and RYR1 gene sequence variations.ScientificWorldJournal2013; 2013: 531465.
54.
GroomL., MuldoonS.M., TangZ.Z., BrandomB.W., BayarsaikhanM., BinaS.Identical de novo mutation in the type 1 ryanodine receptor gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families.Anesthesiology2011; 115: 938–945.
55.
BellringerA.M., ReikenS., DuraM., MurphyP., DengS., LandryD.W.Remodelling of Ryanodine receptor complex causes “leaky” channels: A molecular mechanism for decreased exercise capacity.PNAS2008; 105: 2198–2202.
56.
BellingerA.M., ReikenS., CarlsonC., MongilloM., LiuX., RothmanL.Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle.Nat Med2009; 15: 325–330.
57.
DirksenR.T., AvilaG.Altered ryanodine receptor function in central core disease: leaky or uncoupled Ca(2+) release channels?Trends Cardiovasc Med2002; 12: 189–197.
58.
BellingerA.M., MongilloM., MarksA.R.Stressed out: the skeletal muscle ryanodine receptor as a target of stress.J Clin Invest2008; 118: 445–453.
59.
DowlingJ.J., ArbogastS., HurJ., NelsonD.D., McEvoyA., WaughT.Oxidative stress and successful antioxidant treatment in models of RYR1-related myopathy.Brain2012; 135: 1115–1127.
60.
BendahanD., Kozak-RibbensG., Confort-GounyS., GhattasB., Figarella-BrangerD., AubertM.A Noninvasive Investigation of Muscle Energetics Supports Similarities Between Exertional Heat Stroke and Malignant Hyperthermia.Anesth Analg2001; 93: 683–689.
61.
TarnopolskyM.Effect of caffeine on the neuromuscular system - potential as an ergogenic aid.Appl Physiol Nutr Metab2008; 33: 1284–1289.
62.
IaizzoP.A., JohnsonB.A., NagaoK., GallagherW.J.4-chloro-m-cresol triggers malignant hyperthermia in susceptible swine at doses greatly exceeding those found in drug preparations.Anesthesiology1999; 90: 1723–1732.
63.
SesslerD.I.Temperature monitoring and perioperative ther-moregulation.Anesthesiology2008; 109: 318–338.
64.
GillyH., Wendlmayer-GoettelM., KoberlG., SteinbereithnerK.Anaesthetic uptake and washout characteristics of patient circuit tubing with special regard to current decontamination techniques.Acta Anaesthesiol Scand1992; 36: 621–627.
65.
JonesC., BennettK., KimT.W., BulgerT.F., PollockN.Preparation of Datex-Ohmeda Aestiva and Aisys anaesthetic machines for use in malignant hyperthermia susceptible patients.Anaesth Intensive Care2012; 40: 490–497.
66.
BilmenJ.G., GilliesR.L.Clarifying the role of activated charcoal filters in preparing an anaesthetic workstation for malignant-hyperthermia-susceptible patients.Anaesth Intensive Care2014; 42: 51–58.
67.
McKenzieA., PollockN.Preparation of theatres for malignant hyperpyrexia patients.Anaesth Intensive Care1989; 17: 510–511.
